{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:51:51Z","timestamp":1792612311995,"version":"4.5.0"},"reference-count":43,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32100732"],"award-info":[{"award-number":["32100732"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,5,6]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Oncolytic viruses (OVs) are capable to inflame the tumor microenvironment (TME) and elicit infiltrating tumor-specific T cell responses. However, OV treatment negatively alters the cancer-immune set point in tumors to attenuate the antitumor immune response, which suggests the necessity of dissecting the immune landscape of the virus-treated tumors and developing novel strategies to maximize the potential of OVs. The aim of this study is to investigate the effect of the single-chain variable fragment (scFv)-armed OVs targeting PD-1 on the TME, and ultimately overcome localized immunosuppression to sensitize tumors to immunotherapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A tumor-selective oncolytic herpes simplex virus vector was engineered to encode a humanized scFv against human PD-1 (hPD-1scFv) (YST-OVH). The antitumor efficacy of YST-OVH was explored in multiple therapeutic mouse models. The neurotoxicity and safety of YST-OVH were evaluated in nonhuman primates. The precise dynamics in the TME involved in YST-OVH treatment were dissected using cytometry by time-of-flight (CyTOF).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The identified hPD-1scFv showed superior T-cell activating activity. Localized delivery of hPD-1scFv by YST-OVH promotes systemic antitumor immunity in humanized PD-1 mouse models of established cancer. Immune profiling of tumors using CyTOF revealed the enhanced antitumor effect of YST-OVH, which largely relied on CD8<jats:sup>+<\/jats:sup> T cell activity by augmenting the tumor infiltration of effector CD8<jats:sup>+<\/jats:sup> T cells and establishment of memory CD8<jats:sup>+<\/jats:sup> T cells and reducing associated CD8<jats:sup>+<\/jats:sup> T cell exhaustion. Furthermore, YST-OVH treatment modified the cancer-immune set point of tumors coupled to coexpression of CTLA-4 and TIM-3 on exhausted CD8<jats:sup>+<\/jats:sup> T cells and high levels of CTLA-4<jats:sup>+<\/jats:sup> Treg cells. A combination approach incorporating anti-CTLA-4 or anti-TIM-3 further improved efficacy by increasing tumor immunogenicity and activating antitumor adaptive immune responses. Moreover, this therapeutic strategy showed no neurotoxicity and was well tolerated in nonhuman primates. The benefit of intratumoral hPD-1scFv expression was also observed in humanized mice bearing human cancer cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Localized delivery of PD-1 inhibitors by engineered YST-OVH was a highly effective and safe strategy for cancer immunotherapy. YST-OVH also synergized with CTLA-4 or TIM-3 blockade to enhance the immune response to cancer. These data provide a strong rationale for further clinical evaluation of this novel therapeutic approach.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-004762","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T12:38:11Z","timestamp":1654864691000},"page":"e004762","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":79,"title":["Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade"],"prefix":"10.1136","volume":"10","author":[{"given":"Fei","family":"Ju","sequence":"first","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Luo","sequence":"additional","affiliation":[{"name":"Yangshengtang Co., Ltd, Hangzhou, China"},{"name":"Hangzhou Yangshengtang Biopharmaceutical Co., Ltd, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaolong","family":"Lin","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Jia","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Xu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7219-8138","authenticated-orcid":false,"given":"Rui","family":"Tian","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Lin","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"},{"name":"School of Life Sciences, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Chang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"},{"name":"School of Life Sciences, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Huang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaopeng","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Ren","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaning","family":"Qin","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqin","family":"Yu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizong","family":"Jia","sequence":"additional","affiliation":[{"name":"Beijing Wantai Biological Pharmacy, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinle","family":"Han","sequence":"additional","affiliation":[{"name":"Beijing Wantai Biological Pharmacy, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Luo","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Fu","sequence":"additional","affiliation":[{"name":"School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzhong","family":"Ye","sequence":"additional","affiliation":[{"name":"Beijing Wantai Biological Pharmacy, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8267-1307","authenticated-orcid":false,"given":"Chenghao","family":"Huang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0179-5266","authenticated-orcid":false,"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China"},{"name":"School of Life Sciences, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"2025100308265613000_10.6.e004762.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"2025100308265613000_10.6.e004762.2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med"},{"key":"2025100308265613000_10.6.e004762.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0029-0"},{"key":"2025100308265613000_10.6.e004762.4","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349"},{"key":"2025100308265613000_10.6.e004762.5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.omto.2019.09.004","article-title":"Intravenous injections of a rationally selected oncolytic herpes virus as a potent virotherapy for hepatocellular carcinoma","volume":"15","author":"Luo","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"2025100308265613000_10.6.e004762.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8172"},{"key":"2025100308265613000_10.6.e004762.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2025100308265613000_10.6.e004762.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"2025100308265613000_10.6.e004762.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"2025100308265613000_10.6.e004762.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.07.035"},{"key":"2025100308265613000_10.6.e004762.11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax7992","article-title":"Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade","volume":"12","author":"Nakao","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025100308265613000_10.6.e004762.12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci Transl Med"},{"key":"2025100308265613000_10.6.e004762.13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000857"},{"key":"2025100308265613000_10.6.e004762.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0019-2"},{"key":"2025100308265613000_10.6.e004762.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0014-6"},{"key":"2025100308265613000_10.6.e004762.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663"},{"key":"2025100308265613000_10.6.e004762.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.011"},{"key":"2025100308265613000_10.6.e004762.18","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14340","article-title":"Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity","volume":"8","author":"Zamarin","year":"2017","journal-title":"Nat Commun"},{"key":"2025100308265613000_10.6.e004762.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06954-z","article-title":"Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"2025100308265613000_10.6.e004762.20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ccell.2016.05.012","article-title":"Oncolytic virus-mediated targeting of PGE2 in the tumor alters the immune status and sensitizes established and resistant tumors to immunotherapy","volume":"30","author":"Hou","year":"2016","journal-title":"Cancer Cell"},{"key":"2025100308265613000_10.6.e004762.21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.040557897"},{"key":"2025100308265613000_10.6.e004762.22","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0628"},{"key":"2025100308265613000_10.6.e004762.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x"},{"key":"2025100308265613000_10.6.e004762.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0337-2"},{"key":"2025100308265613000_10.6.e004762.25","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1726168","article-title":"Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens","volume":"9","author":"Luo","year":"2020","journal-title":"Oncoimmunology"},{"key":"2025100308265613000_10.6.e004762.26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700176"},{"key":"2025100308265613000_10.6.e004762.27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15695"},{"key":"2025100308265613000_10.6.e004762.28","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.4049\/jimmunol.155.4.1873","article-title":"Ly-6C is a marker of memory CD8+ T cells","volume":"155","author":"Walunas","year":"1995","journal-title":"J Immunol"},{"key":"2025100308265613000_10.6.e004762.29","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-041015-055318"},{"key":"2025100308265613000_10.6.e004762.30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0516"},{"key":"2025100308265613000_10.6.e004762.31","doi-asserted-by":"crossref","unstructured":"Xia X , Li H , Satheesan S . Humanized NOD\/SCID\/IL2rgammanull (hu-NSG) mouse model for HIV replication and latency studies. J Vis Exp 2019.","DOI":"10.3791\/58255"},{"key":"2025100308265613000_10.6.e004762.32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.10.6477"},{"key":"2025100308265613000_10.6.e004762.33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ebiom.2018.04.020","article-title":"Lighting a fire in the tumor microenvironment using oncolytic immunotherapy","volume":"31","author":"Achard","year":"2018","journal-title":"EBioMedicine"},{"key":"2025100308265613000_10.6.e004762.34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ccell.2021.05.014","article-title":"Oncolytic virotherapy: potentially a game-changing tumor treatment","volume":"39","author":"Kessler","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100308265613000_10.6.e004762.35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98047"},{"key":"2025100308265613000_10.6.e004762.36","doi-asserted-by":"crossref","unstructured":"Xu B , Ma R , Russell L . An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nat Biotechnol 2018.","DOI":"10.1038\/nbt.4302"},{"key":"2025100308265613000_10.6.e004762.37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2311"},{"key":"2025100308265613000_10.6.e004762.38","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26003-6","article-title":"An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma","volume":"12","author":"Xu","year":"2021","journal-title":"Nat Commun"},{"key":"2025100308265613000_10.6.e004762.39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2025100308265613000_10.6.e004762.40","doi-asserted-by":"publisher","DOI":"10.1038\/258152a0"},{"key":"2025100308265613000_10.6.e004762.41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003488"},{"key":"2025100308265613000_10.6.e004762.42","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1718"},{"key":"2025100308265613000_10.6.e004762.43","doi-asserted-by":"crossref","unstructured":"Bommareddy PK , Aspromonte S , Zloza A , et al . MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci Transl Med 2018;10.doi:10.1126\/scitranslmed.aau0417","DOI":"10.1126\/scitranslmed.aau0417"}],"updated-by":[{"DOI":"10.1136\/jitc-2022-004762corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-004762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:27:04Z","timestamp":1759505224000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-004762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,10]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/jitc-2022-004762"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-004762","relation":{"correction":[{"id-type":"doi","id":"10.1136\/jitc-2022-004762corr1","asserted-by":"object"}]},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}